WSJ offers backroom perspective of Allergan vs. Valeant saga
Jeffrey Clark - Posted: 3/26/2015
The Wall Street Journal has published an article entitled Inside the Allergan Battle, a detailed insiders synopsis of the chess game between Allergan, Valeant, Pershing Square and ultimately Actavis, that led to last years biggest corporate acquisiti[...]
Edwards CEO Mussallem addresses Senate
Jeffrey Clark - Posted: 3/25/2015
Advamed went to the Senate yesterday to represent the life sciences industry during a hearing to the Mike Mussallem, Chairman and CEO of Edwards Lifesciences, represented AdvaMed and the interests of the industry itself. Mussallems comments can be fo[...]
Biomarin flying high on strong pipeline
Jeffrey Clark - Posted: 3/24/2015
BioMarin Pharmaceuticals CEO Jean-Jacques Bienaime discusses his companys recent high-flying stock performance and new drugs to treat rare diseases. Biomarin stock is up 67% over the past year, mostly on the promise of its pipeline which includes eig[...]
Novartis wins first FDA approval for biosimilar, to compete with Amgen
Jeffrey Clark - Posted: 3/20/2015
Novartis won FDA approval for its application to market its Zarxio as a biosimilar of Amgens Neupogen. While earlier biosimilars had been approved overseas, this is the first such drug approved by the agency. However, the FDA also stated that the dru[...]
Actavis acquires, becomes the new Allergan
Jeffrey Clark - Posted: 3/18/2015
Actavis has closed it deal to acquire Allergan for $70 Billion.   Just let that sink in for a bit Actavis is now officially part of Big Pharma, as one of the largest 10 pharmaceutical companies in the world. Allergan, which was rumored to be for sale[...]
ReWalk returns post-IPO with plans for growth
Jeffrey Clark - Posted: 3/17/2015
We have covered the growth and PR popularity of ReWalk Robotics in the past.  Late last week, the companys CEO Larry Jasinski, discussed the companys forecast for its ReWalk devices.
Landmark GSK, Novartis asset swap almost complete
Jeffrey Clark - Posted: 3/9/2015
Neither GlaxoSmithKline or Novartis has had an appetite for redefining megamergers in the past few years.   Instead, they have now accomplished the next best thing, swapping assets to reset their strategy and fuel growth for under their existing stru[...]
Boston Scientific, JnJ announce deals
Jeffrey Clark - Posted: 3/4/2015
Perhaps feeling left out of the wave of M&A activity across the pharmaceutical industry, two medical device giants both announced acquisitions this week. Boston Scientific said it will acquire Endos American Medical Systems urology portfolio for up t[...]
Celgene CEO talks pace of change for the future
Jeffrey Clark - Posted: 3/2/2015
Robert Hugin, Celgene Chairman & CEO, discusses his companys $90B market cap, the companys pipeline, and breakthrough treatments for cancer and other diseases. His insight into the pace of change in life sciences and his call to action for the coming[...]
Valeant CEO on CNBC talking Salix deal
Jeffrey Clark - Posted: 2/26/2015
Remember when Lilly CEO John Lechleiter caught so much heat for appearing on CNBC almost every week of the calendar?  Well, Valeant CEO Mike Pearson is making a run at the title. He appeared (on set, of course) with CNBC this week to review his compa[...]
Female Viagra resubmitted to FDA
Jeffrey Clark - Posted: 2/25/2015
Sprout Pharmaceuticals is again seeking FDA approval through a resubmission of its application to market its once-daily non-hormonal pill flibanserin for use in premenopausal women with hypoactive sexual desire disorder. The drug has a fascinating hi[...]
Valeant to pay $14.5B for Salix, another bidder?
Jeffrey Clark - Posted: 2/23/2015
Valeant and Salix both had a relatively horrible year in 2014. Perhaps, they will do better together in 2015. Last year, Valeant spent months trying to acquire Allergan and lost in the end to Actavis. Salix, meanwhile, suffered through severe wholesa[...]
Actavis to adopt Allergan name, poised for growth
Jeffrey Clark - Posted: 2/18/2015
Actavis CEO Brent Saunders briefed CNBC on Wednesday on details regarding the merger with Allergan, including the surprising news that the combined company will adopt the Allergan corporate name. According to Saunders: The acquisition is on track to [...]
John Oliver skewers Big Pharma on Last Week Tonight
Jeffrey Clark - Posted: 2/16/2015
John Oliver, formerly a correspondent with Comedy Centrals The Daily Show, now hosts his own program called Last Week Tonight on HBO. This past weekend, he roasted the global pharmaceutical industry in a segment which is both educational and well, fu[...]
Smart pills: Next generation of blockbuster drugs?
Jeffrey Clark - Posted: 2/12/2015
Even if youve worked a lifetime in the life sciences industry, a new drug class called nootorpics may not be on your radar. The term nootropics refers to a wide range of artificial and natural compounds which are thought to enhance cognitive function[...]
The big picture: Why Pfizer acquired Hospira
Jeffrey Clark - Posted: 2/11/2015
Pfizer agreed to pay about $17 billion in cash and debt to purchase Hospira, which specializes in developing biosimilars and generic versions of injectable treatments.  The acquisition will further expand Pfizers established pharmaceutical business a[...]
Commissioner resigns after six years at FDA
Jeffrey Clark - Posted: 2/9/2015 As reported by Reuters, Dr. Margaret Hamburg is resigning after nearly six years as FDA commissioner.  Hamuburgs tenure marks one of the longest for a modern day head at the FDA and is marked by significant [...]
Obama touts Precision Medicine Initiative
Jeffrey Clark - Posted: 2/4/2015
Building on President Obama’s announcement in his State of the Union Address, the White House is unveiling details about the Precision Medicine Initiative, a bold new research effort to revolutionize the promotion of health and treatment of disease. [...]
Chimerix CEO on Ebola drug, clinical testing in Africa
Jeffrey Clark - Posted: 2/3/2015
Chimerix CEO Michelle Berrey discusses the testing of its Ebola drug in West Africa.
Congressman proposes Big Pharma swear jar
Jeffrey Clark - Posted: 2/2/2015
Just when you think you have heard it all Huffington Post
With wide support, Hatch files Senate bill to repeal medical device tax
Jeffrey Clark - Posted: 1/28/2015
Momentum to repeal the medical device tax is building. The Medical Device Access & Innovation Protection Act, a bipartisan bill to repeal the 2.3% excise tax on medical devices, was introduced in the Senate on Tuesday by Senator Orrin Hatch (R-UT), a[...]
Valeant CEO defends business after losing Allergan to Actavis
Jeffrey Clark - Posted: 1/22/2015
Valeant CEO Mike Pearson claims the company is on a mission to prove allegations against the business model during the Allergan acquisition are not true.  In an interview with Financial Times, Pearson remarks: Part of our thesis was that no one else [...]
Obama supports personalized medicine, life sciences in SOTU speech
Jeffrey Clark - Posted: 1/21/2015
Last night brought President Barack Obamas State of the Union address, during which he announced a provision specific to the life sciences industry. From the SOTU, Obama will ask Congress for funds to launch a precision medicine initiative to acceler[...]
Ariad CEO Harvey Berger at JPMHC
Jeffrey Clark - Posted: 1/21/2015
Ariad CEO Harvey Berger talks commercial success and the companys new cancer drug.
Orexigen CEO Mike Narachi at JPMHC
Jeffrey Clark - Posted: 1/20/2015
Orexigen CEO Mike Narachi talks about its recent obesity drug launch.
BioMarin flying high on s[...]
BioMarin Pharmaceuticals CEO Jean-Jacques Bienaime discusses his company’s recent high-flying stock [...]
ReWalk returns post-IPO w[...]
We have covered the growth and PR popularity of ReWalk Robotics in the past. Late last week, the co[...]
Celgene CEO talks ‘pace o[...]
Robert Hugin, Celgene Chairman & CEO, discusses his company’s $90B market cap, the company’s pipelin[...]
Valeant CEO on CNBC talki[...]
Remember when Lilly CEO John Lechleiter caught so much heat for appearing on CNBC almost every week [...]
Valeant to pay $14.5B for[...]
Valeant and Salix both had a relatively horrible year in 2014. Perhaps, they will do better together[...]